Company Overview and News

1
Michael Hill International names Daniel Bracken as new CEO

2018-09-20 nzherald.co.nz - 1
Michael Hill International has named the head of Specialty Fashion Group as its new chief executive.
MHI MXRHY SFH MXRHF

 
Acquisitions fire Noni B full-year profit

2018-08-29 perthnow.com.au
After coming close to collapse in 2014, women's wear retailer Noni B has produced a fivefold surge in full-year profit and is on track to boost future revenue to $1 billion a year.
NBL SFH

 
Pro-Pac share rout may prove costly for Fahour

2018-08-28 theage.com.au
Our former chief postie, Ahmed Fahour, has ended his latest executive career at Pro-Pac with a profit downgrade and share rout that may prove particularly costly for him.
MQBKY NBL MCQEF MQG SFH

 
Pro-Pac share rout may prove costly for Fahour

2018-08-28 smh.com.au
Our former chief postie, Ahmed Fahour, has ended his latest executive career at Pro-Pac with a profit downgrade and share rout that may prove particularly costly for him.
MQBKY NBL MCQEF MQG SFH

 
Specialty Fashion to start payouts as loss narrows

2018-08-28 theage.com.au
Specialty Fashion Group has reaffirmed its intention to start paying dividends again in the coming year after trimming its full-year loss by 22.4 per cent to $6.97 million.
SFH

 
Specialty Fashion to start payouts as loss narrows

2018-08-28 smh.com.au
Specialty Fashion Group has reaffirmed its intention to start paying dividends again in the coming year after trimming its full-year loss by 22.4 per cent to $6.97 million.
SFH

 
Noni B doubles down on mature womenswear to buck the retail gloom 

2018-07-12 theage.com.au
Middle-age and mature women have not lost their love for shopping and are more likely than the rest of us to venture into the real world when they need a new outfit.
NBL SFH

 
Noni B doubles down on mature womenswear to buck the retail gloom 

2018-07-12 smh.com.au
Middle-age and mature women have not lost their love for shopping and are more likely than the rest of us to venture into the real world when they need a new outfit.
NBL SFH

 
Fashion forward: Ex-PacBrands guru Morphett scores $5m share bonus

2018-06-17 theage.com.au
She was one of the Godfreys board members forced to leave the vacuum cleaner retailer a few weeks back with their tails between their legs after 99.9 year old Godfreys founder John Johnson knocked them out with a low-ball offer.
NBL SFH

 
Fashion forward: Ex-PacBrands guru Morphett scores $5m share bonus

2018-06-17 smh.com.au
She was one of the Godfreys board members forced to leave the vacuum cleaner retailer a few weeks back with their tails between their legs after 99.9 year old Godfreys founder John Johnson knocked them out with a low-ball offer.
NBL SFH

 
Mendy Amzalak wins a tight race with Titomic his best pick

2018-06-09 smh.com.au
In one of the tightest finishes in the history of the Shares Race, Mendy Amzalak of AMZ Capital, has pipped the SMSF Investor, Rob McGovern, at the post to win the four-week game.
SKN SFH

 
Volatile game as Titomic and Bod Australia lift Pritchard to the lead

2018-06-01 smh.com.au
It’s been an action-packed Shares Race this time around, with Richard “the Chartist” Pritchard taking the lead in week three.
SKN KFE WKT SFH

 
Supply crunch as e-commerce shifts into sheds

2018-05-27 theage.com.au
Soaring demand for “last mile” e-commerce delivery is creating a supply crunch in the key industrial precincts in Sydney and Melbourne – and it’s not just new entrant Amazon that’s shaping demand for suitable warehouse facilities.
SFH

 
Supply crunch as e-commerce shifts into sheds

2018-05-27 smh.com.au
Soaring demand for “last mile” e-commerce delivery is creating a supply crunch in the key industrial precincts in Sydney and Melbourne – and it’s not just new entrant Amazon that’s shaping demand for suitable warehouse facilities.
SFH

29
ASX closes higher as a2 Milk and Bellamy's plummet

2018-05-16 theage.com.au
Australian shares closed higher on Wednesday, driven by modest gains from market heavyweights as shares in a2 Milk and Bellamy's fell sharply.
LNK BLT BHP BHPBF BBL BHP BHPLF WHC SFH

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

18h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...